Browsing by Titles
Showing results 1 to 12 of 12
- Lee, Hyun-ju ;
- Kang, Sora ;
- ;
- Park, Jin-Hee ;
- Hwang, Jeong-Woo ;
- Gu, Chan-Hu ;
- Jung, Tae-Mi ;
- Oh, Seokjun ;
- ;
- 2025-07
- Molecular Brain, v.18, no.1
- BioMed Central
- View : 996
- Download : 0
- Lee, Hyun-ju ;
- ;
- Kim, Jun-Su ;
- Kim, Seung-Jae ;
- Jo, Unhui ;
- Jun, Su Jin ;
- Lim, Jongmin ;
- Park, Jin-Yeop ;
- Lee, Myungji ;
- Kim, Donggi ; et al
- 2025-06
- Lee, Hyun-ju. (2025-06). Current Status and Future Directions in the Development of Digital Therapeutic Interventions for Neurodevelopmental Disorders. Clinical Pharmacology and Therapeutics, 117(6), 1632–1636. doi: 10.1002/cpt.3633
- Wiley
- View : 92
- Download : 0
- Ryu, Ka-Young ;
- Lee, Hyun-Ju ;
- Woo, Hanwoong ;
- Kang, Ri-Jin ;
- Han, Kyung-Min ;
- Park, HyunHee ;
- Lee, Sang Min ;
- Lee, Ju-Young ;
- Jeong, Yoo Joo ;
- Nam, Hyun-Wook ; et al
- 2019-10
- Ryu, Ka-Young. (2019-10). Dasatinib regulates LPS-induced microglial and astrocytic neuroinflammatory responses by inhibiting AKT/STAT3 signaling. doi: 10.1186/s12974-019-1561-x
- BioMed Central
- View : 768
- Download : 148
- Lee, Hyun-ju ;
- Choi, Hee-Jeong ;
- ;
- Na, Yoon-Hee ;
- Hong, Jin Tae ;
- Han, Ji Min ;
- ;
- Lim, Key-Hwan
- 2024-06
- Lee, Hyun-ju. (2024-06). Developing theragnostics for Alzheimer's disease: Insights from cancer treatment. International Journal of Biological Macromolecules, 269. doi: 10.1016/j.ijbiomac.2024.131925
- Elsevier
- View : 182
- Download : 81
- ;
- Lee, Hyun-ju ;
- Kim, Jun-Su ;
- Kim, Seung-Jae ;
- Jo, Unhui ;
- Park, Jin Yeop ;
- Jun, Su Jin ;
- Lee, Won Seok ;
- Song, Mingoo ;
- Kim, Donggii ; et al
- 2026-01
- Medicinal Research Reviews, v.46, no.1, pp.316 - 327
- Wiley
- View : 100
- Download : 0
- Choi, Hee-Jeong ;
- ;
- Kim, Jieun ;
- 2023-08
- Choi, Hee-Jeong. (2023-08). EGFR is a potential dual molecular target for cancer and Alzheimer’s disease. Frontiers in Pharmacology, 14. doi: 10.3389/fphar.2023.1238639
- Frontiers
- View : 209
- Download : 22
Article
Erdafitinib diminishes LPS-mediated neuroinflammatory responses through NLRP3 in wild-type mice
- Lee, Hyun-ju ;
- Kim, Se Ha ;
- Jung, Tae-Mi ;
- Kim, Yu-Jin ;
- Gu, Chan-Hu ;
- ;
- Song, Jeong-Heon ;
- 2025-06
- Frontiers in Pharmacology, v.16
- Frontiers Media
- View : 1051
- Download : 10
Article
Erlotinib regulates short-term memory, tau/Aβ pathology, and astrogliosis in mouse models of AD
- Lee, Hyun-Ju ;
- Hwang, Jeong-Woo ;
- Kim, Jieun ;
- Jo, A-Ran ;
- Park, Jin-Hee ;
- ;
- ;
- Kim, Su-Jeong ;
- Song, Jeong-Heon ;
- 2024-10
- Lee, Hyun-Ju. (2024-10). Erlotinib regulates short-term memory, tau/Aβ pathology, and astrogliosis in mouse models of AD. Frontiers in Immunology, 15. doi: 10.3389/fimmu.2024.1421455
- Frontiers Media
- View : 223
- Download : 24
Article
L-DOPA regulates neuroinflammation and Aβ pathology through NEP and ADAM17 in a mouse model of AD
- Lee, Hyun-ju ;
- Nam, Jinhan ;
- Hwang, Jeong-Woo ;
- ;
- ;
- ;
- Kim, Su-Jeong ;
- Jo, A-Ran ;
- 2024-04
- Lee, Hyun-ju. (2024-04). L-DOPA regulates neuroinflammation and Aβ pathology through NEP and ADAM17 in a mouse model of AD. Molecular Brain, 17(1). doi: 10.1186/s13041-024-01092-8
- BioMed Central
- View : 106
- Download : 35
- ;
- Hwang, Jeong-Woo ;
- Lee, Hyun-ju ;
- ;
- ;
- ;
- Seo, Jinsoo ;
- 2023-06
- Park, Jin-Hee. (2023-06). Lomerizine inhibits LPS-mediated neuroinflammation and tau hyperphosphorylation by modulating NLRP3, DYRK1A, and GSK3α/β. Frontiers in Immunology, 14. doi: 10.3389/fimmu.2023.1150940
- Frontiers Media
- View : 278
- Download : 27
- Lee, Hyun-ju ;
- Hwang, Jeong-Woo ;
- ;
- ;
- Jang, Ji-Yeong ;
- 2023-08
- Lee, Hyun-ju. (2023-08). Profiling tyrosine kinase inhibitors as AD therapeutics in a mouse model of AD. Molecular Brain, 16(1). doi: 10.1186/s13041-023-01051-9
- BioMed Central
- View : 131
- Download : 0
- Chae, Sehyun ;
- Lee, Hyun-ju ;
- Lee, Ha-Eun ;
- Kim, Jieun ;
- ;
- Lin, Yuxi ;
- Kim, Hye Yun ;
- Leriche, Geoffray ;
- Ehrlich, Rachel S. ;
- Lingl, Sascha Castro ; et al
- 2024-08
- Chae, Sehyun. (2024-08). The dopamine analogue CA140 alleviates AD pathology, neuroinflammation, and rescues synaptic/cognitive functions by modulating DRD1 signaling or directly binding to Abeta. Journal of Neuroinflammation, 21(1). doi: 10.1186/s12974-024-03180-x
- BioMed Central
- View : 255
- Download : 43
1
